The deal will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more effectively.
Under the deal, Vodafone will provide the technology, infrastructure and expertise for these services, as well as the ability to capture data from several sources to improve overall engagement between patients and their Health Care Professionals (HCPs).
HCPs will give patients the option to use these mHealth services, as an integral part of the patient care process, empowering them to manage their conditions as part of their daily routine.
The partnership will be led by the Intelligent Pharmaceutical Group within AstraZeneca, part of Global Medicines Development, working in close collaboration with the in-country marketing teams.
Vodafone director for Machine to Machine Erik Brenneis said, "AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services."
AstraZeneca VP of Pharmaceutical Innovation Andy Jones said, "Together we believe we are delivering something that will bring real benefit to patients in this important therapeutic area."
Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca.